Downregulation of calcitonin receptor mRNA expression by calcitonin during human osteoclast-like cell differentiation.
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Calcitonin inhibits both osteoclast formation and bone resorption, and is a primary treatment for patients with hypercalcemia and increased bone turnover. However, the clinical utility of calcitonin is limited because patients become refractory to calcitonin after several days (the calcitonin "escape phenomenon"). The molecular basis for calcitonin "escape" is unclear. To determine the regulatory mechanisms controlling calcitonin receptor (CTR) expression in osteoclasts and their precursors, we treated immature mononuclear precursors for human osteoclast-like multinucleated cells (MNC) formed in vitro with 1,25-(OH)2D3, to induce their differentiation to committed mononuclear precursors, and mature multinucleated osteoclasts, and used reverse transcriptase (RT)-PCR to assess expression of CTR mRNA in both committed mononuclear precursors and MNC. The PCR fragment produced was cloned and sequenced to confirm that it was derived from CTR mRNA. CTR mRNA expression was detected in mononuclear MNC precursors after 7 d of 1,25-(OH)2D3 treatment. It was also present in osteoclast-like MNC and highly purified giant cells from osteoclastomas, but not in monocytes or macrophage polykaryons formed in vitro. Calcitonin markedly decreased CTR but not actin mRNA expression in giant cells and MNC after 12 h, and removal of calcitonin restored CTR mRNA expression. Similarly, calcitonin decreased calcitonin-induced adenylate cyclase activity. These data suggest: (a) downregulation of CTR gene expression by calcitonin may in part explain the calcitonin "escape phenomenon"; and (b) expression of CTR mRNA occurs in mononuclear osteoclast precursors within 7 d after exposure to 1,25-(OH)2D3.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The desensitization of the cells to calcitonin was found to be the result of a ligand-induced internalization of the CTR, as well as inhibition of de novo synthesis of the receptor, and has been confirmed in both human and murine osteoclast cultures (194,212).”
From The Activity of Peptides of the Calcitonin Family in Bone (2019) · cites this paper as [194]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease
Chirgwin, J. M., Przybyla, A. E., MacDonald, R. J., & Rutter, W. J. (1979) · Biochemistry · doi:10.1021/bi00591a005 · Cited by 21,725
A highly sensitive adenylate cyclase assay
Salomon, Y., Londos, C., & Rodbell, M. (1974) · Analytical Biochemistry · doi:10.1016/0003-2697(74)90222-x · Cited by 4,169
Pfeilschifter, J., Chenu, C., Bird, A., Mundy, G. R., & Roodman, D. G. (1989) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650040116 · Cited by 468
Nicholson, G. C., Moseley, J. M., Sexton, P. M., Mendelsohn, F. A., & Martin, T. J. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112584 · Cited by 454
CHAMBERS, T. J., McSHEEHY, P. M. J., THOMSON, B. M., & FULLER, K. (1985) · Endocrinology · doi:10.1210/endo-116-1-234 · Cited by 422
Ng, S.-Y., Gunning, P., Eddy, R., Ponte, P., Leavitt, J., Shows, T., & Kedes, L. (1985) · Molecular and Cellular Biology · doi:10.1128/mcb.5.10.2720-2732.1985 · Cited by 372
Davies, J., Warwick, J., Totty, N., Philp, R., Helfrich, M., & Horton, M. (1989) · The Journal of cell biology · doi:10.1083/jcb.109.4.1817 · Cited by 365
KURIHARA, N., CHENU, C., MILLER, M., CIVIN, C., & ROODMAN, G. D. (1990) · Endocrinology · doi:10.1210/endo-126-5-2733 · Cited by 227
Self-citationGorn, A. H., Lin, H. Y., Yamin, M., Auron, P. E., Flannery, M. R., Tapp, D. R., Manning, C. A., Lodish, H. F., Krane, S. M., & Goldring, S. R. (1992) · Journal of Clinical Investigation · doi:10.1172/jci116046 · Cited by 211
Self-citationNg, S. Y., Gunning, P., Eddy, R., Ponte, P., Leavitt, J., Shows, T., & Kedes, L. (1985) · Molecular and Cellular Biology · doi:10.1128/mcb.5.10.2720 · Cited by 209
Research works printed but not linked: 2
- [3]3. Bouizar, Z., W. H. Rostene, and G. Milhaud. 1987. Downregulation of rat kidney calcitonin receptors by salmon calcitonin infusion evidenced by autoradiography. Proc. Natl. Acad. Sci. USA. 84:5125–5128. J.
- [43]43. Lin, M. C., J. Rajfer, R. S. Swerdloff, and N. F. Gonzalez-Cadavid. 1993. Testosterone down-regulates the levels of androgen receptor mRNA in smooth mu 'us at a ti csa avu aia a oa s eusn Steroid Biochem. Mol. Biol. 45(5):333–343.
Cited by
Items 101–124 of 124
Agnusdei, D., Condorelli, L., Gennari, C., Nakamuta, H., & Rico, H. (1996) · Cited by 1
Reddy, S. V., & Roodman, G. D. (2004) · Humana Press eBooks · doi:10.1007/978-1-59259-736-9_14 · Cited by 1
Self-citationThe Osteoclast Molecular Phenotype
Sakai, D. D., & Minkin, C. (1998) · Advances in organ biology · doi:10.1016/s1569-2590(08)60128-7 · Cited by 1
Calcitonin in the Treatment of Osteoporosis
Silverman, S. L. (2006) · Elsevier eBooks · doi:10.1016/b978-0-323-03437-1.50024-5 · Cited by 1
Jablonowski, L. J., & Allen, F. D. (2011) · iDEA - Drexel University Institutional Repository · doi:10.17918/etd-3726 · Cited by 1
Simha, V., Shree, M., Velukur, S. V., & Srivatsa, N. (2023) · EMJ Urology · doi:10.33590/emjurol/10302136 · Cited by 2
Tratamento Farmacológico da Osteoporose em Portugal
de Sousa, O. D., & Rocha, C. C. V. (2008) · Cited by 1
Osteoclastogenesis, Its Control, and Its Defects
Abe, E., Yamate, T., Mocharla, H., Taguchi, Y., & Yamamoto, M. (1998) · Advances in organ biology · doi:10.1016/s1569-2590(08)60122-6
Eficacia de la calcitonina en la prevención de fracturas óseas osteoporóticas. Un metaanálisis
Sáinz-Gil, M. (2008) · UVaDOC UVaDOC University of Valladolid Documentary Repository (University of Valladolid) · doi:10.35376/10324/843
Nunes, R. S., Sinhoreti, M. A. C., Consani, S., & Sobrinho, L. C. (2010) · Brazilian Dental Science · doi:10.14295/bds.2000.v3i1.73
Ueda, K., Nishida, I., Xia, B., Tofani, I., Wang, J., Nishikawa, Y., & Kimura, M. (2004) · Pediatric Dental Journal · doi:10.1016/s0917-2394(04)70002-6
Salmon Calcitonin in the Treatment of Osteopor osis
Goel, A. K. (2010)
Calcitonin: Its Physiological Role and Emerging Therapeutics
Cornish, J., Naot, D., & Martin, T. J. (2012) · Springer eBooks · doi:10.1007/978-1-4471-2745-1_6 · Cited by 2
Hormonal Regulation of Calcium Signaling in Endocrine Cancers
George, N., Changtoo, M., Singh, A., Muthuswamy, S., & Chakraborthy, B. (2014) · World Journal of Endocrine Surgery · doi:10.5005/jp-journals-10002-1141
Salmon Calcitonin: An Update on Its Clinical Utility in Osteoporosis
Chesnut, C. H., & Azria, M. (2009) · Humana Press eBooks · doi:10.1007/978-1-59745-459-9_18
“Physiologic downregulation of calcitonin receptor sites has been reported ( 26 ); however, neither downregulation nor the development of calcitonin antibodies appears to be of clinical relevance (27,28).”
BackgroundEffect of the combination of ipriflavone and 1α-OH-D3 on debilitant bone in growing rats
Ueda, K., Nishida, I., Xia, B., Tofani, I., Wang, J., Nishikawa, Y., & Kimura, M. (2004) · Pediatric Dental Journal · doi:10.11411/pdj.14.5
IN PRACTICE Management of Osteoporosis in CKD Stages 3 to 5
Gordon, P., & Frassetto, L. A. (2010)
Campbell, E. (2017) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/9gcy-e904
Ponticelli, C. (2007) · CRC Press eBooks · doi:10.3109/9780203089903-16
Pignolo, R. J., & Kaplan, F. S. (2008) · Elsevier eBooks · doi:10.1016/b978-0-7216-2872-1.50043-1
What we can learn from fish calcitonin and its receptor: evolutionary insights and medical potential
Yang, Y.-Y., & Liu, J. (2025) · LabMed discovery. · doi:10.1016/j.lmd.2025.100108
di Filippo, L., Franzese, V., Incampo, G., Formenti, A. M., Albanese, L., Doga, M., Onorati, D., Maggiore, R., Rosati, R., Perticone, F., et al. (2026) · Bone · doi:10.1016/j.bone.2026.117872
Ovchinnikova, I. G., Fedorova, O. V., Rasputin, N. A., Кim, G. А., Filatova, E. S., Titova, P. K., Babkov, D. A., Sokolova, E. V., Lukyanov, A. V., Danilov, R. D., et al. (2026) · ChemMedChem · doi:10.1002/cmdc.70485
Metadata
- Authors
- Takahashi, S., Goldring, S., Katz, M., Hilsenbeck, S., Williams, R., & Roodman, G. D.
- Affiliations
- United States Department of Veterans Affairs (US)
- Harvard University (US)
- The University of Texas at San Antonio Health Science Center (US)
- Venue
- Journal of Clinical Investigation
- Published
- 1995-01-01
- Volume
- 95
- Issue
- 1
- Pages
- 167-171
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC295397
- OpenAlex
- W1975884885
- Cited by
- 125
- References
- 44
- Citations by year
- 2026: 2 · 2025: 1 · 2023: 2 · 2021: 3 · 2020: 2 · 2019: 3 · 2018: 2 · 2016: 2 · 2014: 1 · 2013: 1 · 2012: 1
- FWCI
- 3.35
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (1r01am035188-01)
- National Cancer Institute (P30CA 54174)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (AR 39539, AR41336, R01AR041336)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Nephrology › Parathyroid Disorders and Treatments
- Keywords
- calcitonin receptor, calcitonin, osteoclastogenesis, osteoclast-like multinucleated cells, osteoclast precursors, receptor down-regulation, 1,25-dihydroxyvitamin D3, adenylate cyclase, bone resorption, hypercalcemia
- MeSH terms
- Base Sequence, Bone Marrow, Bone Marrow Cells, Calcitonin, Calcitriol, Cell Differentiation, Cells, Cultured, Humans, Macrophages, Molecular Sequence Data, Monocytes, Osteoclasts, RNA, Messenger, Stem Cells, Down-Regulation, Polymerase Chain Reaction, Receptors, Calcitonin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.